CyVek

CyVek is a privately funded biotech company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for testing biomarkers and performing multi-analyte immunoassays.

A profound shift in the paradigm of biomarker testing has taken place – there is a clear and present need to include and measure multiple markers in all facets of research and diagnostics because single markers often fail to provide adequate information. This need has driven CyVek to develop new and creative approaches for measuring multiple markers from small amounts of biological samples rapidly, easily, and with great accuracy and precision. CyVek’s approach (The CyPlex™ System) is based on fundamental innovations in immunoassay design and device architecture. The simplicity, power, speed and flexibility of CyVek’s revolutionary new platform enable researchers and clinicians to achieve major advancements in protein research and immunodiagnostics – not previously attainable using existing technologies.

CyPlex™ offers an incredible breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyPlex™ enables the migration of tests from the bench to the bedside on its versatile and powerful platform. CyPlex™ is envisioned to significantly impact human health and disease by positioning the company to expedite life science research, spur drug discovery activities, and create novel, effective diagnostic tests.

CyVek was founded in 2010 by an experienced team of entrepreneurs that included the founders of CyVera, a successful start-up company that was sold to Illumina in 2005. CyVek is led by an experienced Management Team with a highly successful track record, and is guided by a panel of internationally reputed clinicians and an accomplished Board of Directors.